What is the mechanism of action for Tecvayli (teclistamab-cqyv)?

The active substance in Tecvayli, teclistamab-cqyv, is an antibody that works by activating T-cells (a type of white blood cell) in the immune system to help find and kill multiple myeloma cancer cells in your body. Tecavyli helps to bring together the cancer cell and the T-cell for anti-cancer action.

Tecavyli is classified as a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.

• Tecvayli is a type of protein that attaches to different targets at the same time after it’s injected.
• One part of the drug attaches to CD3 on immune cells called T cells, a type of white blood cell that protects the body from infection and may help fight cancer. Another part of the drug attaches to the B cell maturation antigen (BCMA), a protein found in high levels on myeloma (cancer) cells.
• Once the T-cells and myeloma cells join, the T-cells work to induce cancer cell death.

Tecavyli (teclistamab-cqyv) received accelerated approval in October 2022 to treat adults with multiple myeloma (cancer of cells in bone marrow) that has come back or failed previous treatment. It is used in patients that have received at least 4 prior lines of cancer therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Tecvayli is manufactured by Janssen Pharmaceuticals.

This is not all the information you need to know about Tecvayli (teclistamab-cqyv) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.